Early Data Suggest Novo Nordisk's Long-Acting Insulin Degludec On Par With Sanofi's Lantus

Much anticipated Phase II data suggest Degludec is as good as Lantus, but unseating the market leader will require showing superiority in either maintaining blood glucose control or incidence of hypoglycemia.